A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)
Victoria Atkinson(Greenslopes Private Hospital), Bart Neyns(Universitair Ziekenhuis Brussel), Ana Arance(Hospital Clínic de Barcelona), Rossana Gueli, Pier Francesco Ferrucci(MultiMedica), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Teddy Saliba(Novartis (United States)), Francesca Consoli(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Hiya Banerjee(Tris Pharma (United States)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberta Depenni(University of Modena and Reggio Emilia), Skaistė Tulytė(Vilnius University), Helen Gogas(National and Kapodistrian University of Athens), Massimo Aglietta(Candiolo Cancer Institute), Egbert de Jong(Tris Pharma (United States)), Dimitrios Bafaloukos(Metropolitan Hospital), Pietro Quaglino(Department of Medical Sciences), Ivana Krajsová(Charles University)
Cited by 10
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k